Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 161 articles:
HTML format



Single Articles


    July 2021
  1. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available


    April 2021
  2. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available


  3. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available


  4. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available


    March 2021
  5. SERWAH MA, Omar SA, Khedr MS, Abdel-Hamid AES, et al
    Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97270.
    PubMed     Abstract available


    February 2021
  6. SAHIN M, Sucu P, Serin E, Yetim A, et al
    Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C.
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97302.
    PubMed     Abstract available


    January 2021
  7. EL-NAHAAS SM, Rady NH, Malek S, Serag K, et al
    Changes in serum interferon-gamma-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97309.
    PubMed     Abstract available


  8. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available


  9. YILMAZ B, Kayadibi H, Yeniova AO, Koseoglu H, et al
    The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


  10. PESTANA NF, Equi CMA, Gomes CP, Cardoso AC, et al
    Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    November 2020
  11. LASHEN SA, Metawea MI, Shaaban A
    Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002015.
    PubMed     Abstract available


  12. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018).
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002012.
    PubMed     Abstract available


  13. LITHY RM, Elbaz T, H Abdelmaksoud A, M Nabil M, et al
    Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001972.
    PubMed     Abstract available


  14. RUIZ I, Fourati S, Ahmed-Belkacem A, Rodriguez C, et al
    Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000002003.
    PubMed     Abstract available


    October 2020
  15. OMRAN M, Fouda M, Abdelwahab AO, Nabeel MM, et al
    P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001962.
    PubMed     Abstract available


    September 2020
  16. STEIN K, Stoehr A, Klinker H, Teuber G, et al
    Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001923.
    PubMed     Abstract available


    August 2020
  17. ABDO M, Rabiee A, Abdellatif Z, Abdel Alem S, et al
    Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001903.
    PubMed     Abstract available


  18. NUMAO H, Shimaya K, Kakuta A, Shibutani K, et al
    The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001887.
    PubMed     Abstract available


  19. BEYAN C, Beyan E
    Mean platelet volume to platelet ratio may not be reliable to determine the severity of fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:1067.
    PubMed    


  20. ELSADEK HM, Abdelbaser ES, Emara MH, Soliman HH, et al
    Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Eur J Gastroenterol Hepatol. 2020;32:1046-1053.
    PubMed     Abstract available


    July 2020
  21. GUAN X, Xing F, Li Y
    Alcohol consumption increases the incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis but not in patients with hepatitis C cirrhosis.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001837.
    PubMed     Abstract available


  22. GARRIDO-ESTEPA M, Latasa P, Flores-Herrera J, Garcia Comas L, et al
    Hepatitis C and hepatitis C-related advanced liver disease hospitalisation trends before and after the Strategic Plan for Tackling Hepatitis C in the National Health System.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001841.
    PubMed     Abstract available


  23. CHEN SH, Huang CL, Chiang IP, Chang TC, et al
    Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication.
    Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001833.
    PubMed     Abstract available


  24. MCPHAIL J, Sims OT, Guo Y, Wooten D, et al
    Fibrosis improvement in patients with HCV treated with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.
    PubMed     Abstract available


    June 2020
  25. ABDEL MOEZ AT, El Hawary YA, Al Balakosy AM
    Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients?
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001790.
    PubMed     Abstract available


  26. DA BL, Lourdusamy V, Kushner T, Dieterich D, et al
    Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001786.
    PubMed     Abstract available


    May 2020
  27. QIU LX, Liu YL, Lin W, Liu YR, et al
    Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001749.
    PubMed     Abstract available


  28. TANOGLU A
    Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2020;32:664-665.
    PubMed    


    April 2020
  29. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed     Abstract available


    March 2020
  30. GONZALEZ-COLOMINAS E, Batlle M, Monge-Escartin I, Duran X, et al
    Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response.
    Eur J Gastroenterol Hepatol. 2020 Mar 16. doi: 10.1097/MEG.0000000000001714.
    PubMed     Abstract available


  31. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:378-385.
    PubMed     Abstract available


    January 2020
  32. ABDELSAMEEA E, Alsebaey A, Abdel-Razek W, Ehsan N, et al
    Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C.
    Eur J Gastroenterol Hepatol. 2020 Jan 15. doi: 10.1097/MEG.0000000000001672.
    PubMed     Abstract available


    December 2019
  33. HASSANIN TM, Abdelraheem EM, Abdelhameed S, Abdelrazik M, et al
    Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001647.
    PubMed     Abstract available


  34. RAMACHANDRAN J, Kaambwa B, Muller K, Haridy J, et al
    Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001659.
    PubMed     Abstract available


  35. LIONS C, Laroche H, Zaegel-Faucher O, Ressiot E, et al
    Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001640.
    PubMed     Abstract available


  36. DARWEESH SK, Yosry A, Salah M, Zayed N, et al
    Acoustic radiation forced impulse-based splenic prediction model using data mining for the noninvasive prediction of esophageal varices in hepatitis C virus advanced fibrosis.
    Eur J Gastroenterol Hepatol. 2019;31:1533-1539.
    PubMed     Abstract available


    November 2019
  37. SHOUSHA HI, Saad Y, Saleh DA, Dabes H, et al
    Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001612.
    PubMed     Abstract available


  38. TOSON EA, Shiha GE, El-Sharkawy AM, El-Mezayen HA, et al
    Diagnostic performance of extrinsic apoptosis pathway in hepatitis C virus patients: apoptosis fibrosis crosstalk.
    Eur J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1097/MEG.0000000000001603.
    PubMed     Abstract available


  39. GOZDAS HT, Ince N
    Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001599.
    PubMed     Abstract available


  40. SLIEM HA, Salem AS, Hussien WM, El Sayed HRA, et al
    Arterial wall structural changes in noncirrhotic chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019;31:1432-1438.
    PubMed     Abstract available


  41. WIEGAND J, Buggisch P, Mauss S, Boeker KHW, et al
    Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Eur J Gastroenterol Hepatol. 2019;31:1424-1431.
    PubMed     Abstract available


    October 2019
  42. EL-KHAYAT H, Kamal EM, Mahmoud H, Gomaa A, et al
    Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001581.
    PubMed     Abstract available


  43. HEIL J, Soufidi K, Stals F, Frantzen H, et al
    Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001593.
    PubMed     Abstract available


  44. TACHI Y, Hirai T, Kojima Y, Tachino H, et al
    Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001539.
    PubMed     Abstract available


    September 2019
  45. ABBAS OM, Khalifa KAE, Makhlouf MM, Osman NF, et al
    Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001547.
    PubMed     Abstract available


  46. MORALES-ARRAEZ D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, et al
    Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001534.
    PubMed     Abstract available


  47. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001512.
    PubMed     Abstract available


    August 2019
  48. DURCAN E, Hatemi I, Sonsuz A, Canbakan B, et al
    The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001501.
    PubMed     Abstract available


  49. SARWAR S, Tarique S, Aleem A, Khan AA, et al
    Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
    Eur J Gastroenterol Hepatol. 2019;31:1035-1039.
    PubMed     Abstract available


    June 2019
  50. GARIOUD A, Heng R, Amiot X, Remy AJ, et al
    Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
    Eur J Gastroenterol Hepatol. 2019 Jun 18. doi: 10.1097/MEG.0000000000001450.
    PubMed     Abstract available


    May 2019
  51. HANAFY AS, Seleem WM, Basha MAA, Marei AM, et al
    Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: a dogma or fiction.
    Eur J Gastroenterol Hepatol. 2019 May 29. doi: 10.1097/MEG.0000000000001459.
    PubMed     Abstract available


  52. COSTA M, Rojas Rojas T, Lacoste D, Villes V, et al
    Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441.
    PubMed     Abstract available


    April 2019
  53. CHALOUNI M, Sogni P, Miailhes P, Lacombe K, et al
    Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.
    Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001408.
    PubMed     Abstract available


  54. EMORI CT, Uehara SNO, Carvalho-Filho RJ, Amaral AC, et al
    Changing pattern of chronic hepatitis C in renal transplant patients over 20 years.
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001404.
    PubMed     Abstract available



  55. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy: Erratum.
    Eur J Gastroenterol Hepatol. 2019;31:549.
    PubMed    


  56. ABD-ELSALAM S, Arafa M, Elkadeem M, Elfert A, et al
    Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.
    Eur J Gastroenterol Hepatol. 2019;31:499-502.
    PubMed     Abstract available


    March 2019
  57. ILIAZ R, Yuce T, Torun S, Cavus B, et al
    Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis.
    Eur J Gastroenterol Hepatol. 2019 Mar 25. doi: 10.1097/MEG.0000000000001406.
    PubMed     Abstract available


  58. FOUAD R, Elsharkawy A, Abdel Alem S, El Kassas M, et al
    Clinical impact of serum alpha-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2019 Mar 20. doi: 10.1097/MEG.0000000000001400.
    PubMed     Abstract available


  59. EL-MAKSOUD MA, Habeeb MR, Ghazy HF, Nomir MM, et al
    Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2019 Mar 11. doi: 10.1097/MEG.0000000000001388.
    PubMed     Abstract available


  60. DARWEESH SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, et al
    Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001385.
    PubMed     Abstract available


  61. MUSHTAQ S, Ghani E, Azam K, Hussain T, et al
    Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography.
    Eur J Gastroenterol Hepatol. 2019;31:357-362.
    PubMed     Abstract available


    February 2019
  62. SANDMANN L, Dorge P, Wranke A, Vermehren J, et al
    Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386.
    PubMed     Abstract available


  63. MARCELLIN F, Protopopescu C, Wittkop L, Salmon-Ceron D, et al
    No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Eur J Gastroenterol Hepatol. 2019;31:274-276.
    PubMed    


  64. FAROOQUI MT, Khan MA, Cholankeril G, Khan Z, et al
    Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2019;31:149-156.
    PubMed     Abstract available


    January 2019
  65. ISMAIL WA, Yousef AE
    Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.
    Eur J Gastroenterol Hepatol. 2019 Jan 29. doi: 10.1097/MEG.0000000000001370.
    PubMed     Abstract available


  66. EL-KHAYAT H, Kamal EM, Yakoot M, Gawad MA, et al
    Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients.
    Eur J Gastroenterol Hepatol. 2019 Jan 22. doi: 10.1097/MEG.0000000000001360.
    PubMed     Abstract available


  67. ORMECI N, Sezgin O, Karaali R, Aygen B, et al
    Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
    Eur J Gastroenterol Hepatol. 2019 Jan 21. doi: 10.1097/MEG.0000000000001334.
    PubMed     Abstract available


  68. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.
    Eur J Gastroenterol Hepatol. 2019;31:24-28.
    PubMed     Abstract available


    December 2018
  69. SHEHATA HH, Elfert AA, Abdin AA, Soliman SM, et al
    Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy.
    Eur J Gastroenterol Hepatol. 2018;30:1476-1481.
    PubMed     Abstract available


    November 2018
  70. LYBECK C, Brenndorfer ED, Sallberg M, Montgomery SM, et al
    Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.
    Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316.
    PubMed     Abstract available


  71. DEMERDASH HM, Elyamany AS, Arida E
    Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001306.
    PubMed     Abstract available


    October 2018
  72. SHAHID M, Idrees M, Butt AM, Raza SM, et al
    Hepatitis C and G virus coinfection in Punjab, Pakistan: incidence and its correlation analysis with clinical data.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001302.
    PubMed     Abstract available


  73. LV DD, Wang ML, Chen EQ, Wu DB, et al
    A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001299.
    PubMed     Abstract available


  74. DRIEDGER M, Galanakis C, Doyle MA, Cooper CL, et al
    Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu.
    Eur J Gastroenterol Hepatol. 2018 Oct 30. doi: 10.1097/MEG.0000000000001292.
    PubMed     Abstract available


  75. SHAH T, Hussain W, Ali N, Sardar S, et al
    Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study.
    Eur J Gastroenterol Hepatol. 2018 Oct 24. doi: 10.1097/MEG.0000000000001287.
    PubMed     Abstract available


  76. KRUGER K, Krauth C, Rossol S, Mauss S, et al
    Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-registry.
    Eur J Gastroenterol Hepatol. 2018 Oct 15. doi: 10.1097/MEG.0000000000001283.
    PubMed     Abstract available


  77. IBRAHIM EH, Marzouk SA, Zeid AE, Lashen SA, et al
    Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 2. doi: 10.1097/MEG.0000000000001272.
    PubMed     Abstract available


  78. VAN SANTEN DK, Schim van der Loeff MF, Cartier van Dissel J, Martens JPD, et al
    High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.
    Eur J Gastroenterol Hepatol. 2018;30:1168-1176.
    PubMed     Abstract available


    September 2018
  79. ESSA M, Sabry A, Abdelsameea E, Tharwa ES, et al
    Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Sep 21. doi: 10.1097/MEG.0000000000001250.
    PubMed     Abstract available


  80. ATTIA D, Deterding K, Cornberg J, Gebel MJ, et al
    Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Eur J Gastroenterol Hepatol. 2018 Sep 19. doi: 10.1097/MEG.0000000000001259.
    PubMed     Abstract available


  81. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001264.
    PubMed     Abstract available


  82. FUKUI A, Kawabe N, Hashimoto S, Kamei H, et al
    Skeletal muscle mass depletion in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001255.
    PubMed     Abstract available


  83. STOURNARAS E, Neokosmidis G, Stogiannou D, Protopapas A, et al
    Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254.
    PubMed     Abstract available


    August 2018
  84. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Abstract available


  85. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Abstract available


  86. EL-NAHAAS SM, Fouad R, Elsharkawy A, Khairy M, et al
    High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228.
    PubMed     Abstract available


  87. GAYAM V, Tiongson B, Khalid M, Mandal AK, et al
    Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001233.
    PubMed     Abstract available


  88. ALI N, Hussain W, Hayat A, Shah T, et al
    Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study.
    Eur J Gastroenterol Hepatol. 2018 Aug 3. doi: 10.1097/MEG.0000000000001220.
    PubMed     Abstract available


    July 2018
  89. ELHELBAWY M, Abdel-Razek W, Alsebaey A, Hashim M, et al
    Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001215.
    PubMed     Abstract available


  90. ABDELAZIZ AO, Shousha HI, Said EM, A Soliman Z, et al
    Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2018 Jul 17. doi: 10.1097/MEG.0000000000001196.
    PubMed     Abstract available


  91. SOLUND C, Andersen ES, Mossner B, Laursen AL, et al
    Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192.
    PubMed     Abstract available


  92. HILL LA, Delmonte RJ, Andrews B, Richards L, et al
    Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Jul 2. doi: 10.1097/MEG.0000000000001195.
    PubMed     Abstract available


  93. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed    


  94. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed    


    June 2018
  95. VIEJO LG, Herola AG, Lloret IS, Ruano FS, et al
    Screening of hepatitis C virus infection in adult general population in Spain.
    Eur J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1097/MEG.0000000000001190.
    PubMed     Abstract available


  96. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Abstract available


    May 2018
  97. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Abstract available


  98. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Abstract available


  99. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed    


  100. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Abstract available


  101. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Abstract available


    April 2018
  102. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Abstract available


  103. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Abstract available


  104. SU YC, Lin PC, Yu HC, Wu CC, et al
    Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2018 Apr 4. doi: 10.1097/MEG.0000000000001130.
    PubMed     Abstract available


    February 2018
  105. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Abstract available


  106. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Abstract available


  107. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Abstract available


    January 2018
  108. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Abstract available


  109. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Abstract available


    December 2017
  110. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Abstract available


  111. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Abstract available


  112. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Abstract available


    November 2017
  113. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Abstract available


  114. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Abstract available


    October 2017
  115. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Abstract available


  116. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Abstract available


  117. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Abstract available


  118. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed    


    September 2017
  119. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Abstract available


  120. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Abstract available


  121. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Abstract available


  122. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Abstract available


  123. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Abstract available


    August 2017
  124. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Abstract available


  125. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Abstract available


  126. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Abstract available


  127. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Abstract available


  128. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Abstract available


    July 2017
  129. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Abstract available


    June 2017
  130. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Abstract available


    May 2017
  131. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Abstract available


  132. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed    


  133. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Abstract available


  134. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Abstract available


  135. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Abstract available


    April 2017
  136. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Abstract available


  137. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Abstract available


  138. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Abstract available


    March 2017
  139. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Abstract available


  140. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed    


  141. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Abstract available


    February 2017
  142. ZHENG YX, Zhou PC, Zhou RR, Fan XG, et al
    The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Feb 24. doi: 10.1097/MEG.0000000000000867.
    PubMed     Abstract available


  143. TAVARES RC, Feldner AC, Pinho JR, Uehara SN, et al
    Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2017 Feb 23. doi: 10.1097/MEG.0000000000000866.
    PubMed     Abstract available


  144. RONCERO C, Littlewood R, Vega P, Martinez-Raga J, et al
    Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.
    Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000855.
    PubMed     Abstract available


  145. SU F, Beste LA, Green PK, Berry K, et al
    Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Eur J Gastroenterol Hepatol. 2017 Feb 13. doi: 10.1097/MEG.0000000000000858.
    PubMed     Abstract available


  146. NORTH CS, Pollio DE, Sims OT, Jain MK, et al
    An effectiveness study of group psychoeducation for hepatitis C patients in community clinics.
    Eur J Gastroenterol Hepatol. 2017 Feb 13. doi: 10.1097/MEG.0000000000000860.
    PubMed     Abstract available


  147. SILVA MJ, Pereira C, Loureiro R, Balsa C, et al
    Hepatitis C in a Mobile Low-Threshold Methadone Program.
    Eur J Gastroenterol Hepatol. 2017 Feb 1. doi: 10.1097/MEG.0000000000000843.
    PubMed     Abstract available


  148. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Abstract available


    January 2017
  149. THONNES S, Friedel H, Frohlich H
    The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data.
    Eur J Gastroenterol Hepatol. 2017 Jan 12. doi: 10.1097/MEG.0000000000000819.
    PubMed     Abstract available


    December 2016
  150. TOSON EA, Shiha GE, El-Mezayen HA, Samir W, et al
    Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    November 2016
  151. LAPI F, Capogrosso Sansone A, Mantarro S, Simonetti M, et al
    Hepatitis C virus infection: opportunities for an earlier detection in primary care.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  152. MCEWAN P, Selvapatt N, Brown A, Thursz M, et al
    A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    October 2016
  153. TURNER BJ, Liang Y, Singal A
    FIB-4 and imaging for measuring fibrosis in hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


  154. NORDSTROM EM, Keniston A, Baouchi F, Martinez-Camacho A, et al
    Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    September 2016
  155. WIJARNPREECHA K, Thongprayoon C, Ungprasert P
    Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    August 2016
  156. SCHULZ M, Beha D, Plehm K, Zollner C, et al
    High prevalence of anti-hepatitis E virus antibodies in outpatients with chronic liver disease in a university medical center in Germany.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    July 2016
  157. BERT F, Rindermann A, Abdelfattah MA, Stahmeyer JT, et al
    High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    May 2016
  158. ABDEL-RAZIK A, Elhelaly R, Elzehery R, El-Diasty A, et al
    Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Eur J Gastroenterol Hepatol. 2016;28:599-605.
    PubMed     Abstract available


    March 2016
  159. GULATI R, Nawaz M, Pyrsopoulos NT
    Comparative analysis of online patient education material pertaining to hepatitis and its complications.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    February 2016
  160. CARVALHANA SC, Leitao J, Alves AC, Bourbon M, et al
    Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Abstract available


    December 2015
  161. OZDEN HT
    Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: